STOCK TITAN

Icon Plc - $ICLR STOCK NEWS

Welcome to our dedicated page for Icon Plc news (Ticker: $ICLR), a resource for investors and traders seeking the latest updates and insights on Icon Plc stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Icon Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Icon Plc's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.58%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.42%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.35%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
conferences
Icon Plc

Nasdaq:ICLR

ICLR Rankings

ICLR Stock Data

25.55B
81.31M
0.66%
101.49%
1.68%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
Dublin 18

About ICLR

icon is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. we specialise in the strategic development, management and analysis of programmes that support clinical development - from compound selection to phase i-iv clinical studies. in a highly fragmented industry, we are one of a small group of organisations with the capability and expertise to conduct clinical trials and development projects on either a local or global basis. we have the operational flexibility to provide development services on a stand-alone basis or as part of an integrated “full service” solution. we are also an 'end-to-end'​ pharmacovigilance service provider and this includes post marketing surveillance activities too.